The PE Ratio as of September 2024 (TTM) for Nautilus Biotechnology, Inc. (NAUT) is -5.39

According to Nautilus Biotechnology, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.39. This represents a change of 4.34% compared to the average of -5.17 of the last 4 quarters.

Nautilus Biotechnology, Inc. (NAUT) Historical PE Ratio (quarterly & annually)

How has NAUT PE Ratio performed in the past?

The mean historical PE Ratio of Nautilus Biotechnology, Inc. over the last ten years is -1306.76. The current -5.39 PE Ratio has changed -58.75% with respect to the historical average. Over the past ten years (40 quarters), NAUT's PE Ratio was at its highest in in the December 2019 quarter at 48.66. The PE Ratio was at its lowest in in the March 2021 quarter at -50.82.

Nautilus Biotechnology, Inc. (NAUT) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Nautilus Biotechnology, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Nautilus Biotechnology, Inc. (NAUT) Average PE Ratio

How has NAUT PE Ratio performed in the past?

The current PE Ratio of Nautilus Biotechnology, Inc. (NAUT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Nautilus Biotechnology, Inc. (NAUT) PE Ratio vs. Peers

How is NAUT’s PE Ratio compared to its peers?

Nautilus Biotechnology, Inc.’s PE Ratio is less than C4 Therapeutics, Inc. (-4.07), greater than Kymera Therapeutics, Inc. (-22.58), greater than Foghorn Therapeutics Inc. (-5.60), greater than Revolution Medicines, Inc. (-14.10), less than Century Therapeutics, Inc. (-1.00), less than BioAtla, Inc. (-0.77), less than PMV Pharmaceuticals, Inc. (-1.60), less than Caribou Biosciences, Inc. (-1.48), less than Homology Medicines, Inc. (-0.01), less than Precision BioSciences, Inc. (4.28), greater than Beam Therapeutics Inc. (-14.84), greater than MediciNova, Inc. (-10.93), less than Eliem Therapeutics, Inc. (-3.90), less than Molecular Partners AG (-2.54), greater than Champions Oncology, Inc. (-21.09), less than Cyteir Therapeutics, Inc. (-3.52), greater than Anebulo Pharmaceuticals, Inc. (-5.80), less than Rezolute, Inc. (-4.51), less than HCW Biologics Inc. (-0.59),

Build a custom stock screener for Nautilus Biotechnology, Inc. (NAUT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nautilus Biotechnology, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Nautilus Biotechnology, Inc. (NAUT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Nautilus Biotechnology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.